Inhibition of O-GlcNAcase Using a Potent and Cell-Permeable Inhibitor Does Not Induce Insulin Resistance in 3T3-L1 Adipocytes  by Macauley, Matthew S. et al.
Chemistry & Biology
ArticleInhibition of O-GlcNAcase Using a Potent
and Cell-Permeable Inhibitor Does Not Induce
Insulin Resistance in 3T3-L1 Adipocytes
Matthew S. Macauley,1 Yuan He,2 Tracey M. Gloster,1 Keith A. Stubbs,1,4 Gideon J. Davies,2 and David J. Vocadlo1,3,*
1Department of Chemistry, Simon Fraser University, Burnaby, BC V5A 1S6, Canada
2York Structural Biology Laboratory, Department of Chemistry, University of York, Heslington, York YO10 5DD, UK
3Department of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, BC V5A 1S6, Canada
4Present address: Discipline of Chemistry, School of Biomedical, Biomolecular and Chemical Sciences, University of Western Australia,
35 Stirling Highway, Crawley WA 6009, Perth, Australia
*Correspondence: dvocadlo@sfu.ca
DOI 10.1016/j.chembiol.2010.07.006Open access under CC BY license.SUMMARY
To probe increased O-GlcNAc levels as an inde-
pendent mechanism governing insulin resistance in
3T3-L1 adipocytes, a new class of O-GlcNAcase
(OGA) inhibitor was studied. 6-Acetamido-6-deoxy-
castanospermine (6-Ac-Cas) is a potent inhibitor of
OGA. The structure of 6-Ac-Cas bound in the active
site of an OGA homolog reveals structural features
contributing to its potency. Treatment of 3T3-L1
adipocyteswith 6-Ac-Cas increasesO-GlcNAc levels
in a dose-dependent manner. These increases in
O-GlcNAc levels do not induce insulin resistance
functionally, measured using a 2-deoxyglucose
(2-DOG) uptake assay, or at the molecular level,
determined by evaluating levels of phosphorylated
IRS-1 and Akt. These results, and others described,
provide a structural blueprint for improved inhibitors
and collectively suggest that increased O-GlcNAc
levels, brought about by inhibition of OGA, does
not by itself cause insulin resistance in 3T3-L1
adipocytes.
INTRODUCTION
The hexosamine biosynthetic pathway (HBSP) is a metabolic
pathway enabling adaptation to variations in concentrations of
glucose and other nutrients (Buse, 2006; Marshall, 2006; Teo
et al., 2010). Heightened flux through the HBSP leads to the
onset of insulin resistance (Marshall et al., 1991) and the precise
molecular basis by which this occurs is a topic of great interest
since it could lead to clarity regarding the insulin-desensitizing
effects of hyperglycemia (van Putten and Krans, 1985). One
hypothesis that has emerged is that glucose mediates its effects
through increased posttranslational modification of serine and
threonine residues of nucleocytoplasmic proteins with a single
b-O-linked N-acetylglucosamine residue (O-GlcNAc) (Figure 1A)
(Buse, 2006; Hart et al., 2007). The enzyme installing this modi-
fication is the glycosyltransferase known as O-GlcNAc trans-Chemistry & Biology 17, 937–9ferase (OGT). This enzyme uses as a substrate the activated
donor sugar uridine disphosphate N-acetylglucosamine (UDP-
GlcNAc), which is the end product of the HBSP. Because
increased glucose availability increases flux through the HBSP
and elevates O-GlcNAc levels (Robinson et al., 2007; Walgren
et al., 2003), the O-GlcNAc modification is a candidate nutri-
ent sensing mechanism mediating glucose-induced insulin
resistance.
Several studies in cultured cells (Arias et al., 2004; Park et al.,
2005; Vosseller et al., 2002) as well as in vivo (Dentin et al., 2008;
McClain et al., 2002; Yang et al., 2008) have reported that
elevated cellular O-GlcNAc levels may be a cause of insulin
resistance. These cellular studies have shown that inhibition
of O-GlcNAcase (OGA) usingO-(2-acetamido-2-deoxy-D-gluco-
pyranosylidene)amino-N-phenylcarbamate (PUGNAc) (Fig-
ure 1B) leads to insulin resistance, presumably due to the
increased O-GlcNAc levels stemming from the continuing
action of OGT while OGA function is inhibited (Haltiwanger
et al., 1998). PUGNAc has been shown to decrease insulin-stim-
ulated glucose uptake in cultured 3T3-L1 adipocytes (Vosseller
et al., 2002; Yang et al., 2008), muscle tissue studied ex vivo
(Arias et al., 2004), as well as primary adipocytes (Park et al.,
2005); these studies, which all make use of PUGNAc, have
provided a key part of the foundation for the hypothesis that
increased O-GlcNAc levels cause insulin resistance.
A leading hypothesis for a mechanistic link between increased
O-GlcNAc levels and insulin resistance stems from the observa-
tion that O-GlcNAc and phosphorylation are reciprocal on
certain sites of some proteins (Hart et al., 2007; Wang et al.,
2008) (Figure 1A). Therefore, increased O-GlcNAc levels have
the potential to act as a sensor of excess nutrient availability
and provide negative feedback by modulating phosphorylation
on key signaling proteins and transcription factors in the insulin
signaling cascade (Buse, 2006; Hart et al., 2007). Indeed, several
key proteins involved in insulin signaling, such as Akt (Park et al.,
2005), IRS-1 (Ball et al., 2006), and GSK-3b (Vosseller et al.,
2002), have been found to be O-GlcNAc modified and PUGNAc
has been shown to hinder their phosphorylation (Vosseller et al.,
2002; Whelan et al., 2010; Yang et al., 2008).
PUGNAc is a member of the glyconohydroximolactone family
of inhibitors (Dong and Hart, 1994; Horsch et al., 1991) and is
commonly used to inhibit OGA in biological settings to study48, September 24, 2010 ª2010 Elsevier Ltd All rights reserved 937
Figure 1. Mechanism of OGA and Commonly Used Inhibitors of OGA
(A) TheO-GlcNAcmodification. A percentage of available cellular glucose enters the hexosamine biosynthetic pathway (HBSP) and is converted to UDP-GlcNAc.
One glycosyltransferase that uses UDP-GlcNAc as a substrate is the enzymeO-GlcNAc transferase (OGT). OGT glycosylates nucleocytoplasmic proteins with b-
O-linked GlcNAc residues. Conversely, O-GlcNAcase (OGA) removes O-GlcNAc from modified proteins and imparts a dynamic nature to the O-GlcNAc modi-
fication. Interplay between this O-GlcNAc modification and phosphorylation is thought to give O-GlcNAc the ability to modulate cellular signaling.
(B–D) The chemical structure of PUGNAc (B), NAG-thiazoline (C), and NButGT (D).
(E) OGA uses a mechanism involving substrate-assisted catalysis, which involves the formation of a transient oxazoline intermediate in the first step and subse-
quent hydrolysis of the intermediate to yield the b-anomer of GlcNAc.
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Effect of 6-Ac-Cas on Insulin Sensitivitythe effects of increased O-GlcNAc levels. In addition to OGA,
which belongs to family 84 of glycoside hydrolases (GH84)
(Cantarel et al., 2009), PUGNAc also inhibits members of GH20
with a similar potency (Gao et al., 2001; Macauley et al., 2005).
Consistent with this lack of selectivity, PUGNAc elevates both
O-GlcNAc levels (Haltiwanger et al., 1998) and levels of the
ganglioside GM2 in cultured cells (Ho et al., 2010; Stubbs
et al., 2009). PUGNAc also inhibits enzymes using different cata-
lytic mechanisms including b-N-acetylglucosaminidases from
GH3 (Stubbs et al., 2007) and a-N-acetylglucosaminidases
from GH89 (Ficko-Blean et al., 2008). A second class of inhibitor
that has been used to investigate the function of GH20 andGH84
family members in a biological setting are the thiazoline-based
inhibitors (Knapp et al., 1996, 2007; Macauley et al., 2005; Slaw-
son et al., 2008; Tropak et al., 2004; Yuzwa et al., 2008). Both
1,2-dideoxy-20-methyl-a-D-glucopyranoso-[2,1-d]-D20-thiazo-
line (NAG-thiazoline) (Figure 1C) and PUGNAc are not selective
for GH84 enzymes over GH20 enzymes, whereas 1,2-dideoxy-
20-propyl-a-D-glucopyranoso-[2,1-d]-D20-thiazoline (NButGT)
(Figure 1D) is selective for GH84 enzymes including OGA.
NButGT and NAG-thiazoline have been proposed to mimic
a transition state structurally related to the oxazoline interme-938 Chemistry & Biology 17, 937–948, September 24, 2010 ª2010 Eldiate formed in the active site of enzymes using substrate-
assisted catalysis (Knapp et al., 1996; Whitworth et al., 2007)
(Figure 1E). Like PUGNAc, NAG-thiazoline also elevates levels
of the substrates of both GH20 HexB and GH84 OGA (GM2
and O-GlcNAc, respectively) (Stubbs et al., 2009). NButGT,
which has two extra methylene units appended to the thiazoline
ring (Figure 1D) is 700-fold more potent toward human OGA over
human HexB, which belongs to GH20. Consistent with this
selectivity, NButGT elevates O-GlcNAc levels in cultured cells
without increasing levels of GM2 (Stubbs et al., 2009).
Studies making use of NButGT have shown that the off-target
effects of PUGNAc may be a concern since NButGT does not
recapitulate the insulin-desensitizing effects of PUGNAc in
cultured 3T3-L1 adipocytes (Macauley et al., 2008). Studies
by other laboratories support this finding; NButGT, unlike
PUGNAc, does not hinder activation of Akt in cultured astrocytes
(Matthews et al., 2007) and NButGT does not exacerbate high
glucose-induced insulin resistance in L6 myotubes (Srinivasan
et al., 2009). The surprising absence of any insulin-desensitizing
effects arising from inhibition of OGA using the selective inhibitor
NButGT may stem from one of two possibilities. The first possi-
bility is that NButGT has secondary off-target effects that reversesevier Ltd All rights reserved
Figure 2. 6-Acetamido-6-Deoxy-Castano-
spermine Is a Potent and Competitive Inhib-
itor of Both Human OGA and HexB
(A) Chemical structure of castanospermine.
(B) Chemical structure of 6-acetamido-6-deoxy-
castanospermine (6-Ac-Cas).
(C and D) Kinetic results for the inhibition of human
OGA with 6-Ac-Cas. Velocities are reported as
arbitrary absorbance units.
(E and F) Kinetic results for the inhibition of human
HexB with 6-Ac-Cas. Velocities are reported as
arbitrary absorbance units.
(C and E) Reciprocal Lineweaver-Burk plots
clearly demonstrate the competitive nature of inhi-
bition by 6-Ac-Cas for both enzymes.
(D and F) A plot of the apparent KM against
the concentration of 6-Ac-Cas reveals KI values
of 300 and 250 nM toward OGA and HexB,
respectively.
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The second possibility is that increased O-GlcNAc levels are
not an independent mechanism leading to insulin resistance
and it is PUGNAc that has off-target effects that induce insulin
resistance. This distinction is an important one since PUGNAc
continues to be widely used in studies designed to elucidate
the biological roles ofO-GlcNAc, without concern over its poten-
tial off-target effects (Kim et al., 2009; Lee et al., 2010; Nagy
et al., 2010; Whelan et al., 2010; Yanagisawa and Yu, 2009).
One way to aid in discriminating which inhibitor has off-target
effects, and establish whether increased O-GlcNAc levels inde-
pendently induce insulin resistance in cultured cells, would be
to use a structurally distinct inhibitor of OGA. Here, we describe
a new OGA inhibitor that has a different structure compared
with both PUGNAc and NButGT. We find 6-acetamido-6-
deoxy-castanospermine (6-Ac-Cas) elevates O-GlcNAc levels
but does not cause insulin resistance in 3T3-L1 adipocytes.
Further, experiments in which PUGNAc and NButGT or 6-Ac-
Cas are used in parallel and in combination indicate these
compounds all increase O-GlcNAc levels to the same extent
yet only PUGNAc induces insulin resistance; these studies also
show that neither NButGT nor 6-Ac-Cas reverse insulin resis-Chemistry & Biology 17, 937–948, September 24, 2010tance induced by PUGNAc. Last, we find
that using low doses of PUGNAc, which
still increase O-GlcNAc levels does not
show any insulin-desensitizing effects.
These findings collectively support the
idea that increased O-GlcNAc levels,
stemming from inhibition of OGA, are not
an independent mechanism governing
the development of insulin resistance in
3T3-L1 adipocytes and indicate caution
should be used when using PUGNAc in
biological settings.
RESULTS AND DISCUSSION
To clarify whether PUGNAc or NButGT
has off-target effects and to establish ifincreased O-GlcNAc levels independently induce insulin resis-
tance in cultured cells, we sought a structurally distinct inhibitor
of OGA. One broad class of inhibitors that has proven widely
useful for inhibition of many glycoside hydrolases are the imino-
sugars; these inhibitors have an endocyclic nitrogen in place of
the ring oxygen. This class of inhibitor is thought tomimic a disso-
ciative oxocarbenium ion-like transition state structure in which
the positive charge is distributed over the anomeric center and
the ring oxygen (Lillelund et al., 2002). One member of this class
of inhibitor is castanospermine (Figure 2A), a natural product that
was originally isolated from Castanospermum australe (Hohen-
schutz et al., 1981). Castanospermine is an iminosugar in which
an ethylene unit links the endocyclic nitrogen to create a fused
5,6-ring system, which is typically a low micromolar inhibitor of
glucosidases (Gloster et al., 2007). A derivative of castanosper-
mine bearing an acetamido group at the 6-position (correspond-
ing to the 2-position of glucopyranose) has been described as
a submicromolar inhibitor of some GH20 family members (Liu
et al., 1991; Tropak et al., 2004). This derivative, 6-Ac-Cas
(Figure 2B), is structurally different from both the thiazoline-
based inhibitors and PUGNAc and is also charged at physiolog-
ical pH. Given its obvious structural and physical differences, weª2010 Elsevier Ltd All rights reserved 939
Table 1. Data Collection and Structure Refinement Statistics for
the Complex of BtGH84 with 6-Ac-Cas
Chemistry & Biology
Effect of 6-Ac-Cas on Insulin Sensitivityfelt this was a good candidate compound to investigate as an
inhibitor of OGA.BtGH84 - 6-Ac-Cas
Data Collection
Space group P1
Cell dimensions
a, b, c (A˚) 51.5, 94.0, 98.8
a, b, g () 104.1, 93.9, 103.1
Resolution (A˚) 50.00–2.00 (2.07–2.00)
Rmerge 0.054 (0.452)
I / sI 15.4 (2.0)
Completeness (%) 98 (97)
Redundancy 2.4 (2.4)
Refinement
Resolution (A˚) 2.0Inhibition of Human OGA and HexB by 6-Ac-Cas
Using 4-nitrophenyl 2-acetamido-2-deoxy-b-D-glucopyranoside
(pNP-GlcNAc) as a substrate, the mode of inhibition and KI
values of 6-Ac-Cas for OGA and HexB were determined
(Figures 2C–2F). 6-Ac-Cas acts as a competitive inhibitor toward
both enzymes with KI values of 300 and 250 nM for OGA (Figures
2C and 2D) andHexB (Figures 2E and 2F), respectively. Although
6-Ac-Cas does not show selectivity for either enzyme, we felt
that 6-Ac-Cas would be a good candidate to probe whether
NButGT or PUGNAc has off-target effects. Prior to initiating
studies using 6-Ac-Cas in cultured cells, we elected to investi-
gate the structural aspects of OGA inhibition by 6-Ac-Cas and
its similarities and dissimilarities with NButGT and PUGNAc.No. reflections 108,834
Rwork / Rfree 0.20/0.24
No. atoms
Protein 10,398
Ligand/ion 32
Water 394
B-factorsa
Protein 44
Ligand/ion 30
Water 42
Rmsds
Bond lengths (A˚) 0.020
Bond angles () 1.59
aAtomic B-values include the TLS contribution.Structure of BtGH84 in Complex with 6-Ac-Cas
A bacterial homolog of human OGA, also belonging to family
GH84 of glycoside hydrolases, from Bacteroides thetaiotaomi-
cron (BtGH84) was used for structural studies since it has been
shown that it is a good model of the human enzyme (Martinez-
Fleites et al., 2010). 6-Ac-Cas inhibits BtGH84 with a KI value
of 220 nM, which closely matched the Kd obtained using
isothermal titration calorimetry (see Figure S1 available online).
The structure of BtGH84 cocrystallized with 6-Ac-Cas was
solved in the original P1 crystal form (Dennis et al., 2006) at
a resolution of 2.0 A˚ (see Table 1 for data processing and refine-
ment statistics). Unambiguous electron density shows that 6-Ac-
Cas binds in the1 subsite (Davies et al., 1997) as with previous
BtGH84 inhibitors (Figure 3A). 6-Ac-Cas is observed in an
approximate 1,4B / 4E conformation (Vocadlo and Davies,
2008), which is very similar to the conformations reported previ-
ously for castanospermine bound to b-glucosidases (Cutfield
et al., 1999; Gloster et al., 2007) and reflects distortion of the
inhibitor away from the 4C1 chair conformation observed in solu-
tion (Hohenschutz et al., 1981). In the retaining b-glucosidase
complexes with castanospermine, it is assumed that there is
a key interaction between the protonated nitrogen and the
nucleophilic carboxylate. Here, consistent with an active site
evolved for substrate-assisted catalysis, the acetamido carbonyl
oxygen lays 2.9 A˚ ‘‘below’’ the amine moiety of castanosper-
mine, within hydrogen bonding distance (Figure 3B). Beyond
this key interaction, 6-Ac-Cas binds similarly to other inhibitors
such as NAG-thiazoline (Dennis et al., 2006) and PUGNAc
(Macauley et al., 2008). The only difference is a slight change
in the position normally occupied by the C6 hydroxyl group,
which likely reflects avoidance of a steric clash between
Val314 and His433 and the five-membered ring of 6-Ac-Cas
(Figure 3C). Overall, this structure highlights how inhibitors with
different structures can bind within the enzyme active site in
a similar manner. The extensive hydrogen-bonding between
6-Ac-Cas and active site residues is reflected in the highly
favorable enthalpy of binding (DH 8.4 ± 0.5 kcal mol-1); there
is also a small favorable entropic contribution to binding
(TDS +0.6 kcal mol-1) (Figure S1). The 1:1 stoichiometry between
BtGH84 and 6-Ac-Cas (Figure S1) is consistent with the
observed competitive inhibition derived from kinetics.940 Chemistry & Biology 17, 937–948, September 24, 2010 ª2010 ElEffect of 6-Ac-Cas on O-GlcNAc Levels in 3T3-L1
Adipocytes
To test if 6-Ac-Cas can permeate into cells and inhibit OGA to
increase O-GlcNAc levels, it was incubated with differentiated
3T3-L1 adipocytes for different periods of times and at different
doses of the compound. The 3T3-L1 cell line has been used
extensively to study the insulin signaling cascade and the devel-
opment of insulin resistance; it is also the cell line in which
PUGNAc was originally found to induce insulin resistance (Vos-
seller et al., 2002). As shown in Figure 4A, 6-Ac-Cas elevates
O-GlcNAc levels in a dose-dependent manner. Densitometric
analysis of the complete set of bands in the western blots (see
Figure S2 for information on densitometry methods and linear
response range for lysates) yields an EC50 value of 9 mM (Fig-
ure 4B), which is consistent with the potency (KI = 600 nM) and
theEC50 value of 8 mM that we determined previously for NButGT
in this cell line (Macauley et al., 2008). 6-Ac-Cas also elevates
O-GlcNAc levels in a time-dependent manner (Figures 4C and
4D), with a trend consistent to those observed previously for
both NButGT and PUGNAc in this cell line (Macauley et al.,
2008). For further studies into the effects of 6-Ac-Cas on insulin
sensitivity we chose to use an overnight (16 hr) treatment and
a dose of 100 mM, in part to be consistent with previous studies
(Macauley et al., 2008; Vosseller et al., 2002) and, in part,sevier Ltd All rights reserved
Figure 3. Structure of 6-Ac-Cas Bound in
the Active Site of BtGH84
(A) Observed electron density (Fobs-Fcalc ‘‘omit’’
map, contoured at 3s in divergent stereo) for
6-Ac-Cas bound to BtGH84 (PDB 2XJ7).
(B) Schematic diagram showing the interactions
between 6-Ac-Cas and BtGH84. All residues
shown are conserved in the human GH84 O-
GlcNAcase. Hydrogen-bond interactions between
protein and ligand (%3 A˚) are shown as dashed
lines with the distance in A˚.
(C) Superposition of 6-Ac-Cas in complex
with BtGH84 (PDB 2XJ7) with NAG-thiazoline in
complex with BtGH84 (PDB 2CHN).
For additional details supporting data from this
figure, see Table S1 and Figure S1.
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Effect of 6-Ac-Cas on Insulin Sensitivitybecause this treatment protocol, with any of the three inhibitors
increases O-GlcNAc to indistinguishable levels (Figure 4E) that
are approximately 10-fold higher than control cells (Figure 4F).
Effect of 6-Ac-Cas on Insulin-Stimulated 2-DOG
in 3T3-L1 Adipocytes
To assess the effect of 6-Ac-Cas on insulin sensitivity, 2-deoxy-
glucose (2-DOG) uptake was determined over 5 min in response
to either 0 or 10 nM insulin. Insulin induced an 8-fold increase in
2-DOG uptake compared with control cells. Cells that had been
pretreated overnight with 100 mM 6-Ac-Cas took up indistin-
guishable amounts of 2-DOG compared with control cells
(Figure 5). The lack of effect 6-Ac-Cas has on insulin-mediated
2-DOG uptake parallels what is observed in cells treated with
NButGT. However, the absence of any insulin-desensitizing
effect arising from 6-Ac-Cas treatment, exactly as observed
with NButGT treatment, contrasts with the decrease in insulin-
stimulated 2-DOG uptake observed when cells are treated with
PUGNAc (Figure 5).
Effect of 6-Ac-Cas on Insulin Signaling in 3T3-L1
Adipocytes
PUGNAc has been shown to perturb the insulin signaling
pathway by hindering phosphorylation-dependent activation of
Akt at Thr308 (Macauley et al., 2008; Vosseller et al., 2002;
Yang et al., 2008). A more recent report tracked this effect
upstream in the insulin signaling pathway to suggest that it
may stem from a defect in phosphorylation of the insulin receptor
substrate (IRS-1) (Whelan et al., 2010). Phosphorylation of
mouse IRS-1 at Tyr608 (Tyr612 in human IRS-1) (EspositoChemistry & Biology 17, 937–948, September 24, 2010et al., 2003) and Akt at Thr308 (Sale and
Sale, 2008) are both key events in the
insulin signaling cascade. Therefore,
monitoring insulin-mediated phosphory-
lation at these residues of IRS-1 and Akt
is a useful measure of insulin sensitivity
at the molecular level that compli-
ments functional 2-DOG uptake assays.
PUGNAc caused a statistically signifi-
cant 2-fold decrease in insulin-stimulated
phosphorylation of Akt at Thr308 (p =
0.007) and a 40% decrease in insulin-stimulated phosphorylation of IRS-1 (p = 0.07) (Figure 6A). On
the other hand, neither NButGT nor 6-Ac-Cas perturbed
insulin-mediated phosphorylation of either Akt or IRS-1 (Figures
6B and 6C). These findings are consistent with the effects of
these three compounds on the 2-DOG uptake. IRS-1 has been
demonstrated to be O-GlcNAc modified (Park et al., 2005), and
the major sites of modification were mapped to the C terminus
of the protein (Ball et al., 2006; Klein et al., 2009). To investigate
if the three inhibitors increased O-GlcNAc modification of IRS-1,
IRS-1 was immunoprecipitated from 3T3-L1 adipocytes treated
with PUGNAc, NButGT, 6-Ac-Cas, or vehicle alone. As shown in
Figure 6D, all three inhibitors increasedO-GlcNAc levels on IRS-
1 to comparable extents, which is in keeping with their use at
concentrations well above their respective EC50 values.
Effect of Mixing PUGNAc with NButGT on Insulin
Resistance in 3T3-L1 Adipocytes
3T3-L1 adipocytes were treated with PUGNAc or NButGT
or both together in order to test if NButGT has an effect that
mitigates insulin resistance. Cotreatment of the two inhibitors
resulted in the same increase in O-GlcNAc levels compared
with treatment of either inhibitor alone (Figure 7A). Cotreatment
of PUGNAc and NButGT resulted in the same 25% decrease in
2-DOG uptake that is observed when cells are treated with
PUGNAc alone (Figure 7B). The results at the molecular level
agree with this finding; cotreatment did not reverse the defect
in activation of Akt compared with cells treated with PUGNAc
alone (Figure 7C). The same results on the activation of
Akt were observed with cotreatment of cells with PUGNAc
and 6-Ac-Cas (Figure S3). These results strongly suggest thatª2010 Elsevier Ltd All rights reserved 941
Figure 4. 6-Ac-Cas Produces Dose- and
Time-Dependent Increases in O-GlcNAc-
Modified Proteins in 3T3-L1 Cells
(A) Fully differentiated 3T3-L1 adipocytes were
treated with various doses of 6-Ac-Cas for 24 hr
and evaluated for levels of O-GlcNAc by western
blot.
(B) Densitometric analysis of (A) showing the effect
of various doses of 6-Ac-Cas on levels of
O-GlcNAc-modified proteins reveals an EC50
value of 9 mM. Values shown are reported relative
to those found for untreated control cells.
(C) Cells treated with 100 mM 6-Ac-Cas display a
time-dependent increase in levels of O-GlcNAc-
modified proteins.
(D) Densitometric analysis of (C) showing the effect
of 100 mM 6-Ac-Cas on levels of O-GlcNAc-modi-
fied proteins over time. Values shown are reported
relative to those found for untreated control cells.
(E) Direct comparison of 3T3-L1 adipocytes
treated for 16 hr with 100 mM PUGNAc, NButGT,
or 6-Ac-Cas reveals that all three inhibitors elevate
levels of O-GlcNAc-modified proteins to an
equivalent extent over untreated cells. Levels of
O-GlcNAc-modified proteins were analyzed by
western blot analysis using anti-O-GlcNAc anti-
body (CTD110.6) (upper panels) and anti-b-tubulin
to evaluate protein loading (lower panels).
(F) Densitometric analysis of (E) shows that 100 mM
PUGNAc, NButGT, and 6-Ac-Cas all elevate levels
ofO-GlcNAc-modified proteins to the same extent
(approximately 10-fold above untreated cells).
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Effect of 6-Ac-Cas on Insulin SensitivityNButGT and 6-Ac-Cas do not have off-target effects that can
reverse insulin resistance.
Effect of Using a Low Dose of PUGNAc on Insulin
Resistance in 3T3-L1 Adipocytes
PUGNAc is approximately 12 times more potent than NButGT
under physiological conditions (pH 7.4) (Macauley et al., 2005;
Yuzwa et al., 2008). Consistent with this, we previously demon-
strated that PUGNAc has a lower EC50 value than NButGT in
3T3-L1 adipocytes (Macauley et al., 2008). The studies that
have shown PUGNAc causes insulin resistance (Arias et al.,
2004; Vosseller et al., 2002; Yang et al., 2008), including our
previous study (Macauley et al., 2008) and the results presented
above, have used PUGNAc at a concentration of 100 mM or
higher. These concentrations are significantly above the 3 mM942 Chemistry & Biology 17, 937–948, September 24, 2010 ª2010 Eltr
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gsevier Ltd All rights reseEC50 value for PUGNAc and so we
assessed the effect of PUGNAc on insulin
sensitivity of 3T3-L1 adipocytes at
a lower concentration closer to the EC50
value yet still well above the KI value. At
1 mM, PUGNAc still caused a dramatic
elevation of O-GlcNAc levels. These
levels were maximal at 10 mM PUGNAc
since O-GlcNAc levels were indistin-
guishable between cells treated with 10
and 100 mMPUGNAc (Figure 7D). Despite
the increased O-GlcNAc levels present in
cells treated with 1 mM PUGNAc, thiseatment regimen did not blunt insulin-stimulated 2-DOG
lucose uptake (Figure 7E). Consistent with this observation,
mM PUGNAc did not perturb insulin-stimulated activation of
kt (Figure 7F). At 10 mM PUGNAc, there was only a small and
tatistically insignificant (p > 0.05) decrease in insulin-stimulated
Akt levels (Figure 7F). These results contrast with the insulin-
esensitizing effect produced by 100 mM PUGNAc despite the
distinguishable differences in the levels of O-GlcNAc in cells
eated with 10 versus 100 mM PUGNAc.
Together, the studies presented here using 6-Ac-Cas, the
otreatment of cells with PUGNAc and NButGT or 6-Ac-Cas,
nd the low concentration studies using PUGNAc, all suggest
at the insulin-desensitizing effect of PUGNAc is not due to inhi-
ition of OGA leading to increasedO-GlcNAc levels. Interestingly,
anglioside levels have been proposed to impact insulin signalingrved
Figure 5. 6-Ac-Cas Does Not Affect Insulin-Mediated 2-DOGUptake
in 3T3-L1 Adipocytes
3T3-L1 adipocytes were treated overnight (16 hr) with either 6-Ac-Cas,
NButGT, or PUGNAc. The following day, the cells were serum starved for
four hours, stimulated with (open bars) or without (closed bars) 10 nM insulin
prior to monitoring 2-DOG uptake over a period of 5 min. Values are reported
as the relative fold increase in 2-DOG uptake over cells that were not treated
with insulin.
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both inhibit OGA as well as the lysosomal GH20 b-hexosamini-
dases responsible for degradation of gangliosides. The observa-
tion that 6-Ac-CAS does not induce insulin resistance in 3T3-L1
adipocytes is therefore notable because it suggests that inhibition
of these lysosomal b-hexosaminidases is not the mechanism by
which PUGNAc induces insulin resistance. It is possible to enter-
tain various other scenarios as to the off-target effects of PUGNAc
that induce insulin resistance. Because PUGNAc has an aromatic
aglycon one scenario might be that it could act as a substrate
decoy for cellular glycosyl transferases (Lugemwa and Esko,
1991), which could lead to perturbations in cell surface glycosyla-
tion. Alternatively, PUGNAc could act as an inhibitor of glucose
transport. Such a scenario is unlikely to be the mechanism since
molecular effects on the insulin signaling pathway are observed
with PUGNAc treatment. One intriguing possibility is that the
oxime carbamate moiety of PUGNAc may be reactive enough to
serve as an acylating agent. This possibility is supported by the
observation that compounds related to PUGNAc can break
down in aqueous solution (Macauley et al., 2005) and the noted
requirement that addition of inhibitor to the media is needed for
extend periods of time when treating cells (Haltiwanger et al.,
1998; Slawson et al., 2005). Indeed, oxime carbamates have
been used as activity-based proteomics profiling probes
(Li et al., 2007). Though PUGNAc does have off-target effects,
the basis of these effectsmayprove to be an interesting tangential
line of research leading to new targets in the insulin signaling
pathway.
The results we describe showing that increased O-GlcNAc
does not on its own lead to insulin resistance find con-
ceptual support from a study that showed that decreasing
O-GlcNAc levels in 3T3-L1 adipocytes, through several genetic
approaches, did not reverse insulin resistance caused by
culturing cells in high glucose (Robinson et al., 2007). It is impor-
tant to note that in spite of these findings in cultured cells,Chemistry & Biology 17, 937–9a number of other studies have observed signs of insulin resis-
tance or perturbed glucohomeostasis in vivo when OGT is over-
expressed (Dentin et al., 2008; Housley et al., 2008; McClain
et al., 2002; Yang et al., 2008). Differences between pharmaco-
logical and genetic methods used to increase O-GlcNAc levels
could be one explanation (Knight and Shokat, 2007). Alterna-
tively, because several of these genetic studies have been
carried out in vivo it is possible that it is only in the complex
setting found within live animals that insulin resistance may
develop. To date, however, no studies have investigated the
effects of pharmacologically elevated O-GlcNAc levels on
glucohomeostasis in vivo. In the next article (Macauley et al.,
2010) (this issue of Chemistry & Biology), we describe the use
of NButGT in vivo and use various experimental paradigms to
test the effects that increasedO-GlcNAc levels have on glucoho-
meostasis.SIGNIFICANCE
The discovery of OGA inhibitors has made critical contribu-
tions to the field of O-GlcNAc biology, enabling evaluation
and generation of hypotheses as to the functional roles of
O-GlcNAc in cells. Earlier inhibitors such as streptozotocin
have been shown, through elegant studies, to have clear
off-target effects (Gao et al., 2000; Pathak et al., 2008). Like
streptozotocin, PUGNAc has been widely used and has
been important for establishing the dynamic nature of
O-GlcNAc and for providing key support for the nutrient
sensing hypothesis. Despite concerns about its selectivity,
PUGNAc continues to be used to study the function of
O-GlcNAc. To clarify whether newer selective inhibitors
such as NButGT have off-target effects, or, alternatively,
whether it is PUGNAc that has off-target effects, we have
sought new structurally distinct inhibitors of OGA. Here,
we describe 6-Ac-Cas as a class of OGA inhibitor, distinct
from both PUGNAc and NButGT, which acts efficiently in
cells to increaseO-GlcNAc levels in a dose- and time-depen-
dent manner. The co-crystal structure ofBtGH84 in complex
with 6-Ac-Cas reveals the molecular basis for inhibition of
OGA. This structure presents a blueprint that should enable
the future design of derivatives based on this scaffold that
are selective for either OGA or HexB. The concordance of
results showing that neither 6-Ac-Cas nor NButGT cause
insulin resistance in 3T3-L1 adipocytes strongly points to
the insulin-desensitizing effects of PUGNAc arising from
off-target effects. These data suggest that caution should
be used when interpreting data obtained using PUGNAc in
a biological setting. Overall, our studies suggest that phar-
macological elevation of O-GlcNAc levels do not induce
insulin resistance in 3T3-L1 adipocytes. The results should
stimulate further study into the inhibition of OGA in vivo
and open the way for using different classes of inhibitors
to probe O-GlcNAc biology.EXPERIMENTAL PROCEDURES
General
NButGT was prepared as described previously (Macauley et al., 2005).
PUGNAc and 6-Ac-Cas were obtained from Toronto Research Chemicals48, September 24, 2010 ª2010 Elsevier Ltd All rights reserved 943
Figure 6. Treatment of 3T3-L1 Adipocytes with 6-Ac-Cas or NButGT Does Not Perturb in Insulin-Mediated Activation of Akt or IRS1
(A–C) Cells were treated with 100 mM (A) PUGNAc, (B) NButGT, or (C) 6-Ac-Cas overnight. The following day, after a 4 hr serum starvation some of the cells were
treated with 10 nM insulin. All cells were harvested and analyzed by western blot analysis using the CTD110.6 anti-O-GlcNAc, anti-b-tubulin, anti-Akt, anti-
pThr308Akt, anti-IRS-1, and anti-pTyr608IRS-1 antibodies. Densitometry of the bands corresponding to pAkt or pIRS-1 relative to total Akt and IRS-1, respec-
tively, are plotted to the right of the blots.
(D) IRS-1 was immunoprecipitated from control cells as well as cells treated overnight with PUGNAc, NButGT, or 6-Ac-Cas. The resulting immunoprecipitates
were probed by western blot forO-GlcNAc and IRS-1. TheO-GlcNAc levels on IRS-1 from cells treated with each of the three inhibitors are all elevated compared
with O-GlcNAc levels on IRS-1 from control cells.
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Effect of 6-Ac-Cas on Insulin Sensitivityand Industrial Research Limited, respectively. pNP-GlcNAcwas obtained from
Sigma. Dexamethasone and isobutylmethylxanthine were obtained from
Sigma. Insulin was obtained from Eli Lilly. Human OGA was recombinantly
expressed as described previously (Cetinbas et al., 2006). Human HexB was
obtained from Sigma.
Inhibition by 6-Ac-Cas Human OGA and HexB
To determine the inhibition constant of 6-Ac-Cas for OGA, a continuousUV/Vis
assay was carried out using 4-nitrophenyl 2-acetamido-2-deoxy-b-D-gluco-
pyranoside as a substrate. The substrate was varied between 50 mM to
3.5 mM and inhibitor concentration was varied between 50 nM to 2 mM.
The apparent KM at each inhibitor concentration was determined and plotted
against the inhibitor concentration. In this manner, the KI could be calculated
as the negative of the valuewhere the best-fit line crossed the x axis. The buffer
conditions and precise details of how the assay was carried out have been
described previously (Cetinbas et al., 2006).
BtGH84 Structure Solution and Refinement
The complex of BtGH84 with 6-Ac-Cas was obtained by soaking apo crystals,
which were obtained as described previously (Dennis et al., 2006), with a small
quantity of powdered 6-Ac-Cas. Crystals were obtained in space group P1
with cell dimensions a = 51.2 A˚, b = 92.7 A˚, c = 98.8 A˚, a = 103.0, b =
95.0, and g = 101.3 and with two molecules of BtGH84 in the asymmetric
unit. X-ray diffraction data were collected at the European Synchrotron944 Chemistry & Biology 17, 937–948, September 24, 2010 ª2010 ElRadiation Facility (ESRF, Grenoble) on beam-line ID23-1 to 2.0 A˚ resolution
(details in Table 1), and data were processed with MOSFLM (Leslie, 1992).
All other crystallographic computing used the CCP4 suite unless otherwise
stated. The structure was refined, using the original apo structure (Dennis
et al., 2006) as the starting model, with REFMAC (Murshudov et al., 1997)
and model building and addition/inspection of solvent molecules and inhibitor
was performed using COOT (Emsley and Cowtan, 2004). Electron density
figures were prepared with BOBSCRIPT (Esnouf, 1997).
Cell Culture
3T3-L1 preadipocytes were obtained from Dr. Green at Harvard Medical
School. 3T3-L1 adipocytes were cultured as preadipocytes and then differen-
tiated into adipocytes using a previously reported protocol (Macauley et al.,
2008). For 2-DOG uptake assays, cells were differentiated in 12-well plates,
whereas for experiments aimed at assessing the phosphorylation of IRS-1
and Akt, the cells were differentiated in 6-well plates. All assays with 3T3-L1
adipocytes took place 10–12 days after differentiation; a time in which >95%
of cells displayed adipocyte morphology.
2-DOG Uptake
Fully differentiated 3T3-L1 adipocytes were treated overnight (16 hr) with the
appropriate dose of inhibitor. The following day, the media was removed, cells
were washed once with a large volume of PBS, DMEM containing low glucose
(5 mM) without serumwas added and cells were incubated for 4 hr. During thissevier Ltd All rights reserved
Figure 7. Cotreatment of PUGNAc and NButGT as Well as a Low Dose of PUGNAc Strongly Suggests that Elevated O-GlcNAc Levels Do Not
Cause Insulin Resistance in 3T3-L1 Adipocytes
(A) Assessment of O-GlcNAc levels in 3T3-L1 adipocytes treated overnight (16 hr) with either 100 mM PUGNAc, NButGT, or both.
(B) 2-DOG uptake assay in 3T3-L1 adipocytes treated overnight with 100 mMPUGNAc, NButGT, or both. Cells were stimulated with (open bars) or without (closed
bars) 10 nM insulin. Values are reported as the relative fold increase in 2-DOG uptake over cells that were not treated with insulin.
(C) A parallel set of cells were treated identically as in (B) except cells were used for western blot analyses and probed using anti-Akt and anti-pThrAkt antibodies.
The lower panel represents densitometry of pAkt levels standardized to total Akt levels. Errors represent the standard deviation between the three independent
replicates.
(D) Assessment of O-GlcNAc levels in 3T3-L1 adipocytes treated overnight (16 hr) with 0, 1, 10, or 100 mM PUGNAc.
(E) 2-DOG uptake assay in 3T3-L1 adipocytes treated overnight with or without 1 mM PUGNAc. Cells were stimulated with (open bars) or without (closed bars)
10 nM insulin. Values are reported as the relative fold increase in 2-DOG uptake over cells that were not treated with insulin.
(F) Cells treated with 0, 1, 10, or 100 mMPUGNAc were stimulated with 10 nM insulin as in (E) except cells were used for western blot analyses and probed using
anti-Akt and anti-pThrAkt antibodies. The lower panel represents densitometry of pAkt levels standardized to total Akt levels. Errors represent the standard devi-
ation between the three independent replicates.
For additional experiments supporting data from this figure, see Figure S3.
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night. This media was then removed, cells were washed twice with PBS, and
cells were incubated in Krebs-Ringer Phosphate (KRP) buffer. After 15 min,
insulin was added to somewells to a final concentration of 10 nM. After another
15 min, [1-3H] 2-DOG (0.5 mCi/ml, 100 mM) (Moravek Radiochemicals) was
added to the cells and after precisely 5 min the assay was terminated. To
ensure that assays were stopped at the same time, the liquid in the plates
was dumped into a discard bucket and the plates were submerged in 1 liter
of cold PBS. The plate was then submerged into a second fresh bucket of
PBS, then dried on paper towel, and 500 ml of Triton X-100 was added to
each well. After thorough homogenization of the contents in each well by
pipetting the contents up and down approximately ten times, 300 ml was
used for scintillation counting to determine the amount of 2-DOG taken up
into cells.
Western Blotting
The assay was identical to the 2-DOG uptake assay except, following the
15 min of insulin stimulation, the contents of the cells were removed and
300 ml of 13 SDS-PAGE loading buffer was added to each well. The contents
of each well were carefully transferred into a conical tube and heated at 95C
for 15 min. The lysates were directly used for western blotting using proce-
dures outlined previously (Macauley et al., 2008) with the only modification
being that for blots toward Akt, pAkt, IRS-1, or pIRS-1 5% nonfat milk powder
in PBS containing 0.1% Tween 20 (PBS-T) was used to initially block the nitro-Chemistry & Biology 17, 937–9cellulose membrane. For western blot analysis, between 10 and 50 mg of
protein from lysates was used to load each lane. Exposure times of films to
nitrocellulose membranes ranged from between 5 and 30 s. For the Akt and
pAkt blots, shorter washing times (15 min total compared with 1 hr total) after
the primary and secondary antibodies was used. The Akt and pAkt antibodies
were obtained from Cellular Signaling Technologies and used at a dilution of
1:1000. The anti-IRS-1 antibody used for western blotting was obtained
from Santa Cruz Biotechnology and used at a dilution of 1:2000, while
the pIRS-1 antibody was obtained from Upstate and used at a dilution of
1:2000. The anti-IRS-1 antibody used for immunoprecipitations was obtained
fromUpstate. TheRL2 anti-O-GlcNAc antibodywas obtained fromAbcam and
used at a dilution of 1:1000. The CTD110.6 anti-O-GlcNAc antibody was
obtained from Covance and used at a dilution of 1:4000. The anti-b-tubulin
antibody was obtained from the Developmental Studies Hybridoma Bank
and used at a dilution of 1:2500. All secondary antibodies were HRP-conju-
gated, obtained from Santa Cruz Biotechnology, and used at a dilution of
1:20,000.
Preparation of 3T3-L1 Lysates for Immunoprecipitation
Differentiated 3T3-L1 adipocytes in 10 cm culture dishes were treated with
inhibitors overnight (16 hr). The following day, the media was removed and
cells were washed with 5 ml of PBS. Cells were then gently scrapped off the
plate in 10 ml of PBS and pelleted by centrifugation (10 min, 250 rcf).
The supernatant was carefully decanted and the pellets were stored48, September 24, 2010 ª2010 Elsevier Ltd All rights reserved 945
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ing 0.5% nonidet P-40 (Ipegal) along with protease inhibitors (Roche) and
1 mM NButGT. The pellets were passed through a 27 gauge needle three
times, rocked for 30 min at 4C, and sonicated twice for 20 s. The solutions
were centrifuged (10min, 17,000 rcf) to remove insoluble debris and the super-
natant was gently removed and set aside. To this supernatant, an equal
volume (0.5 ml) of 1,1,1-trichloro-2,2,2,-trifluoroethane was added, and the
mixture was inverted approximately ten times, in order to sequester lipids.
This solution was centrifuged (10 min, 17,000 rcf) and the top layer was
removed and used in the immunoprecipitations.
Immunoprecipitation of IRS-1
Lysates from 3T3-L1 adipocytes, prepared using the protocol described
above, were incubated with 10 ml of anti-IRS-1 antibody. The solutions were
gently rocked at 4C for 2 hr. Protein A/G beads (40 ml, Calbiochem) were
then added to capture the primary antibody and these mixtures were further
rocked at 4C for an hour. The beads were centrifuged (30 s, 2000 rcf) and
the supernatant was gently removed. The beads were washed with 1 ml of
cold lysis buffer by inverting the tube ten times. Following another spin and
removal of this supernatant, the washing procedures were repeated once
more with lysis buffer and then once with cold PBS for a total of three washes.
After the final wash, after which the beads were sucked dry and 80 ml of 13
SDS-PAGE loading buffer was added, the beads were heated at 95C for
15min, and then finally centrifuged (30 s, 2000 rcf). The supernatant was gently
removed and set aside to use for western blots.
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